32 results about "MMP3" patented technology

The invention belongs to the field of cosmetics and particularly relates to an anti-aging composition and preparation and application thereof. The anti-aging composition is prepared from the following ingredients in parts by weight: 1 to 3 parts of hydrolyzed pearl powder, 1 to 3 parts of dioscorea villosa root extract, 0.5 to 2 parts of acetyl hexapeptide-8, 0.5 to 2 parts of acetyl octapeptide-3 and 0.5 to 2 parts of nonapeptide-1. Experiments prove that the anti-aging composition disclosed by the invention has an extremely obvious removing effect on quiescent wrinkles, dynamic wrinkles and posture extrusion wrinkles, meanwhile can obviously promote multiplication of human skin fibroblast, extremely obviously promotes synthesis of I and III type collagen and extremely obviously inhibits expression of MMP1 and MMP3.

Compositions / methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment / stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and / or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and / or RCC patient is also presented.

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

The invention discloses a biomarker for predicting the prognosis of esophageal squamous cell carcinoma, including the screening of the prognostic marker based on public big data, the verification of the prognostic marker and the detection of the efficacy of the prognostic marker. This study first discovered and confirmed that ANO1 combined with MMP3 protein can be used as a biomarker to predict the prognosis of esophageal squamous cell carcinoma. The combination of methods can significantly improve the accuracy of prognosis prediction for patients with esophageal squamous cell carcinoma. The study also found that the ANO1 gene was highly expressed in cancer tissues of patients with esophageal squamous cell carcinoma, and its increased expression could promote the proliferation, invasion and metastasis of esophageal squamous cell carcinoma. Cell carcinoma progression in vivo and in vitro.

A composition for preventing and / or treating piles contains at least one NO synthetase (NOS) inhibitor, especially iNOS inhibitor, at least one vascular angiogenesis inhibitor, especially VEGF inhibitor, and at least one matrix metal proteinase (MMP) inhibitor, especially MMP1, MMP3, MMP9 and / or MMP12 inhibitor.

An in vitro method of determining the type of a fibroepithelial tumour of the breast in a biological sample is provided. The method comprises the steps of obtaining an expression profile of one or more genes selected from the group consisting of PRAME, ADH1 B, CTHRC1, NPTX2, NEFL, ABCA8, DAPL1, TP63_v2, COL17A1, GCNT2, CCL19, MMP3, FN1, TRERF1, TRIM29, TESC, KIF20A, UHRF1, HEPACAM2, APOD, SERHL2. KIF15, HOXD13, GAGE2B, CALML5, C2orf40, ADH1C, CYP1B1, SPAG11B, GRB7, UBE2C, SYNGAP1, TP63_v1, LAMB1, OR5P3, SPC25, SHISA2, SCARA5, LHX2, RORC, DPYSL4, CH25H, and CHST1 in a sample and determining the differential activity of the one or more genes relative to a control; correlating the differential activity of the one or more genes relative to the control to obtain a p-score; and determining the type of fibroepithelial tumour based on the p-score, wherein a p-score of less than 0.5 is indicative of a fibroadenoma and a p-score of 0.5 and above is indicative of phyllodes tumour. Particularly, the said method is exemplified using an expression profile of five genes comprising of PRAME, FN1, CCL19, ABCA8 and APOD. A method for managing the treatment of a subject with a fibroepithelial tumour of the breast is also provided as well as a kit when used in the methods of the present invention.

The invention relates to a separated nucleic acid sequence of a total number born trait related gene MMP3 of a pig in the technical field of genetic engineering. The separated nucleic acid sequence is provided with a sequence shown by an SEQ ID No:1, the length of which is 1346bp; the nucleic acid sequence shows a pair of allele-specific nucleic acid primers the lengths of which are 20bp; the pair of nucleic acid primers is specifically hybridized; and the sequence shown by the SEQ ID No:1 containing an eighth exon, a ninth exon and an eighth intron of the MMP3 gene of the pig is amplified. The implementation and the application of the separated nucleic acid sequence can be used for detecting and judging the quality of total number born traits of the pig; the molecular marker is applied to conduct a marker assisted selection during breeding of the pig, thereby correcting the defect during conventional selection of reproductive traits of the pig; and the separated nucleic acid sequencehas important practical significance.

The invention discloses a solid tumor combined treatment composition, the effective components at least include mmp3 antagonistic substance and oncolytic virus. The invention uses the mmp3 antagonistic substance and the oncolytic virus to treat solid tumors in combination, which can effectively inhibit the growth of the tumor and improve the survival rate.

The invention relates to a gene molecular marker related to yak physique, a detection method and a kit, and belongs to the technical field of molecular biology. The invention analyzes the genetic polymorphism of the yak MMP3 gene to find a SNP site of the MMP3 gene that can affect the physique of the yak; the invention also provides a PCR method for detecting the SNP site. Molecular breeding of yak can be better carried out by the above method.

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind: i) the IIICS isoform of fibronectin, ii) matrix-metalloproteinase 3 (MMP3), iii) periostin, or iv) tenascin-W.